Molecular deregulation induced by silencing of the high mobility group protein A2 gene in retinoblastoma cells

Molecular Vision

Volumn 18, Issue , 2012, Pages 2420-2437

  Venkatesan, Nalini ^a   Krishnakumar, Subramanian ^a   Deepa, Perinkulam Ravi ^b   Deepa, Murali ^c   Khetan, Vikas ^d   Ashwin Reddy, M ^e  

^a VISION RESEARCH FOUNDATION   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c MEDICAL RESEARCH FOUNDATION   (India)

^d Moorfields Eye Hospital ^*  (United Kingdom)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP A2 PROTEIN; MATRIX METALLOPROTEINASE; PROTEIN P53; RAS PROTEIN; UVOMORULIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MAPPING; GENE SILENCING; HMGA2 GENE; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION; ZYMOGRAPHY;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; EYE PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HMGA2 PROTEIN; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETINOBLASTOMA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84867489427     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Dyer MA, Rodriguez-Galindo C, Wilson MW. Use of preclinical models to improve treatment of retinoblastoma. PLoS Med 2005; 2:e332-[PMID: 16231976].
2. Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TJ, Cebulla CM. Targeting Hypoxia, a Novel Treatment for Advanced retinoblastoma. Invest Ophthalmol Vis Sci 2008; 49:2799-805. [PMID: 18326690].
3. Krishnakumar S, Mohan A, Mallikarjuna K, Venkatesan N, Biswas J, Shanmugam MP, Ren-Heidenreich L. EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci 2004; 45:4247-50. [PMID: 15557427].
4. Mitra M, Kandalam M, Verma RS. UmaMaheswari K, Krishnakumar S. Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Mol Vis 2010; 16:828-42. [PMID: 20461151].
5. Mitra M, Misra R, Harilal A, Sahoo SK, Krishnakumar S. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis 2011; 17:2724-37. [PMID: 22065926].
6. Mitra M, Kandalam M, Sundaram CS, Verma RS, Maheswari UK, Swaminathan S, Krishnakumar S. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Invest Ophthalmol Vis Sci 2011; 52:5441-8. [PMID: 21546534].
7. Burr DB, Molina SA, Banerjee D, Low DM, Takemoto DJ. Treatment with connexin 46 siRNA suppresses the growth of human Y79 retinoblastoma cell xenografts in vivo Exp Eye Res 2011; 92:251-9. [PMID: 21320488].
8. Venkatesan N, Kandalam M, Pasricha G, Sumantran V, Manfioletti G, Ono SJ, Reddy MA, Krishnakumar S. Expression of High mobility group A2 Protein in retinoblastoma and its Association With Clinicopathologic Features. J Pediatr Hematol Oncol 2009; 31:209-14. [PMID: 19262251].
9. Chau KY, Manfioletti G, Cheung-Chau KW, Fusco A, Dhomen N, Jane CS, Tetsuo S, Shizuo M, Ono SJ. Derepression of HMGA2 Gene Expression in retinoblastoma Is Associated with Cell Proliferation. Mol Med 2003; 9:154-65. [PMID: 14571323].
10. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001; 277:63-81. [PMID: 11602345].
11. Boo LM, Lin HH, Chung V, Zhou B, Louie SG, O'Reilly MA, Yen Y, Ann DK. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damagedependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 2005; 65:6622-30. [PMID: 16061642].
12. Reeves R, Nissen MS. The A.T. DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990; 265:8573-82. [PMID: 1692833].
13. Sgarra R, Rustighi A, Tessari MA. Nuclear phospho-proteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004; 574:1-8. [PMID: 15358530].
14. Hebert C, Norris K, Mark A Scheper NN, John J. Sauk High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma Mol Cancer 2007; 6:5-[PMID: 17222355].
15. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U. Bullerdiek J. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996; 149:775-9. [PMID: 8780382].
16. Gattas GJ, Quade BJ, Nowak RA, Morton CC. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 1999; 25:316-22. [PMID: 10398424].
17. Wunderlich V, Bottger M. High mobility group proteins and cancer: an emerging link. J Cancer Res Clin Oncol 1997; 123:133-40. [PMID: 9119878].
18. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M. Goldmann T, Vollmer E, Bullerdiek J. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 2007; 46:503-11. [PMID: 17477356].
19. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, Atomi Y. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 2003; 89:2104-9. [PMID: 14647145].
20. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 1997; 19:153-6. [PMID: 9254881].
21. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004; 64:2024-9. [PMID: 15026339].
22. Andrieux J, Demory JL, Dupriez B, Quief S, Plantier I, Roumier C, Bauters F, Lai JL, Kerckaert JP. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 2004; 39:82-7. [PMID: 14603445].
23. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008; 6:663-73. [PMID: 18403645].
24. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A. HMGA2 protein expression correlates with lymphnode metastasis and increased tumor grade in pancreaticductal adenocarcinoma. Mod Pathol 2009; 22:43-9. [PMID: 18843278].
25. Tzatsos A, Bardeesy N. Ink4a/Arf regulation by let-7b and Hmga2: a genetic pathway Governing stem cell aging. Cell Stem Cell 2008; 3:469-70. [PMID: 18983959].
26. Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stemcell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 2008; 135:227-39. [PMID: 18957199].
27. Park SM, Shell S, Radjabi AR. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007; 6:2585-90. [PMID: 17957144].
28. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007; 104:11400-5. [PMID: 17600087].
29. Li AY, Boo LM, Wang SY, Lin HH, Wang CC, Yen Y, Chen BP, Chen DJ, Ann DK. Suppression of nonhomoloG0us end joining repair by overexpression of HMGA2. Cancer Res 2009; 69:5699-706. [PMID: 19549901].
30. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei JJ. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 2011; 71:349-59. [PMID: 21224353].
31. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V, Fusco A. Inhibition of HMGI-C protein synthesis sup-presses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995; 15:1545-53. [PMID: 7862147].
32. Pentimalli F, Dentice M, Fedele M, Pierantoni GM, Cito L, Pallante P, Santoro M, Viglietto G, Dal Cin P, Fusco A. Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Cancer Res 2003; 63:7423-7. [PMID: 14612541].
33. Cui T, Leng F. Specific Recognition of AT-Rich DNA Sequences by the Mammalian High Mobility Group Protein AT-hook 2: A SELEX Study. Biochemistry 2007; 46:13059-66. [PMID: 17956125].
34. Watanabe M, Sheriff S, Lewis KB, Tinch SL, Cho J, Balasubramaniam A, Kennedy MA. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett 2012; 315:18-27. [PMID: 22036895].
35. Chantada G, Doz F, Antoneli CB, Grundy R, Clare Stannard FF, Dunkel IJ, Grabowski E, Leal-Leal C, Rodríguez-Galindo C, Schvartzman E, Popovic MB, Kremens B, Meadows AT, Zucker JM. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006; 47:801-5. [PMID: 16358310].
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Methods 2001; 25:402-8. [PMID: 11846609].
37. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207-10. [PMID: 11752295].
38. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM, Kobayashi SV, Lim L, Burchard J, Jackson AL, Linsley PS, Cleary MA. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28:2167-74. [PMID: 18212054].
39. Monte M. The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem 2003; 278:30356-64. [PMID: 12750368].
40. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126:121-34. [PMID: 16839881].
41. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells. Mol Cell 2001; 7:673-82. [PMID: 11463391].
42. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. PUMA is an essential mediator of p53-dependent and-independent apoptotic pathways. Cancer Cell 2003; 4:321-8. [PMID: 14585359].
43. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006; 45:72-82. [PMID: 16180235].
44. Piboonniyom SO, Timmermann S, Hinds P, Münger K. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell car-cinoma lines preferentially affect INK4A gene and result in increased cdk6 activity. Oral Oncol 2002; 38:179-86. [PMID: 11854066].
45. Ch'ng S, Sullivan M, Yuan L, Davis P, Tan ST. Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma. Cancer Cell Int 2006; 6:28-[PMID: 17177999].
46. Eshkoor SA, Ismail P, Rahman SA, Mirinargesi M, Oshkour SA. Increased protein expression of p16 and cyclin D1 in squamous cell carcinoma tissues. Biosci Trends. 2009; 3:105-9. [PMID: 20103831].
47. Chen D. Clinicopathologic Features of CDK6 Translocation-Associated B-Cell Lymphoproliferative Disorders. Am J Surg Pathol 2009; 33:720-9. [PMID: 19145199].
48. Chévez-Barrios P, Hurwitz MY, Louie K, Marcus KT, Holcombe VN, Schafer P, Aguilar-Cordova CE, Hurwitz RL. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol 2000; 157:1405-12. [PMID: 11021842].
49. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains Oncogenic RAS-induced Epithelial-Mesenchymal Transition in Human Pancreatic cancer cells. Am J Pathol 2009; 174:854-68. [PMID: 19179606].
50. Jiao W, Miyazaki K, Kitajima Y. Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br J Cancer 2002; 86:98-101. [PMID: 11857019].
51. Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R, Nagayama M. Reverse correlation of E-cadherin and Snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol 2001; 37:65-71. [PMID: 11120485].
52. Poser I, Domínguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK. Bosserhoffs. Loss of E-cadherin expressionin melanoma cells involves upregulation of the transcriptional Repressor Snail. J Biol Chem 2001; 276:24661-6. [PMID: 11323412].
53. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, Nieto MA. Connecting estrogen receptor function, transcriptional repression and E-cadherin expression in breast cancer. Oncogene 2002; 21:3241-[PMID: 12082640].
54. Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, Cano A. SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res 2007; 67:11721-31. [PMID: 18089802].
55. Olmeda D, Montes A, Moreno-Bueno G, Flores JM, Portillo F, Cano A. Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. Oncogene 2008; 27:4690-701. [PMID: 18408755].
56. Wang C, Liu X, Huang H, Ma H, Cai W, Hou J, Huang L, Dai Y, Yu T, Zhou X. Deregulation of Snai2 is associated with metastasis and poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2012; 130:2249-58. [PMID: 21647877].
57. Haraguchi M, Okubo T, Miyashita Y, Miyamoto Y, Hayashi M, Crotti TN, McHugh KP, Ozawa M. Snail regulates cell-matrix adhesion by regulation of the expression of integrins and basement membrane proteins. J Biol Chem 2008; 283:23514-23. [PMID: 18593711].
58. Haraguchi M. The role of the transcriptional regulator snail in cell detachment, reattachment and migration. Cell Adhesion & Migration 2009; 3:259-63. [PMID: 19287205].
59. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival:implications in development and cancer. Development 2005; 132:3151-61. [PMID: 15983400].
60. Adithi M, Nalini V, Kandalam M, Krishnakumar S. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma. J Pediatr Hematol Oncol 2007; 29:399-405. [PMID: 17551402].
61. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001; 276:8403-8. [PMID: 11113133].
62. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 2000; 275:32167-73. [PMID: 10900205].
63. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98:12485-90. [PMID: 11606713].
64. Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R, Ziche M. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 2000; 14:1674-6. [PMID: 10973914].